Warning: Undefined array key "S1" in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\Myelofibrosis.php on line 2
Myelofibrosis
LE WE PMID CA
Myelofibrosis1877Myelofibrose

Essential thrombocythemia

Hypereosinophilic syndrome

JAK2V617F

Leukemia (chronic myeloic)

Leukemia (chronic neutrophilic)

Mastocytosis

MPLW515L

Myelofibrosis

Myeloproliferative syndromes

PCD (Multiple myeloma and other plasma cell dyscrasias)

Polycythemia vera

Pomalidomide

Receptor (Erythropoietin)

Receptor (G CSF)

Receptor (Thrombopoietin)

Spleen (Splenomegaly)

2007  
1
Validation and comparison of contemporary prognostic models in primary myelofibrosis: analysis based on 334 patients from a single institution.
[17407134] Cancer 109(10): 2083-8 (2007)
2005  
2
New approaches in the treatment of myelofibrosis.
[15565565] Cancer 103(1): 32-43 (2005)
2006  
3
Advances in the therapy of chronic idiopathic myelofibrosis.
[16951397] Oncologist 11(8): 929-43 (2006)
2010  
4
Pomalidomide: a new IMiD with remarkable activity in both multiple myeloma and myelofibrosis.
[20095057] Am J Hematol 85(2): 95-6 (2010)
2008  
5
Essential thrombocythemia, polycythemia vera, and myelofibrosis: current management and the prospect of targeted therapy.
[18429051] Am J Hematol 83(6): 491-7 (2008)
2001  
6
Pathology of autoimmune myelofibrosis. A report of three cases and a review of the literature.
[11488067] Am J Clin Pathol 116(2): 211-6 (2001)
2008  
7
From palliation to epigenetic therapy in myelofibrosis.
[19074063] Hematology Am Soc Hematol Educ Program -(-): 83-91 (2008)
2007  
8
Biology and treatment of primary myelofibrosis.
[18024650] Hematology Am Soc Hematol Educ Program -(-): 346-54 (2007)
2009  
9
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment.
[18988864] Blood 113(13): 2895-901 (2009)
2009  
10
How I treat symptomatic splenomegaly in patients with myelofibrosis.
[19332765] Blood 113(22): 5394-400 (2009)
2007  
11
Primary myelofibrosis and its paraneoplastic stromal effects.
[17488678] Haematologica 92(5): 577-9 (2007)
2006  
12
Classification, diagnosis and management of myeloproliferative disorders in the JAK2V617F era.
[17124067] Hematology Am Soc Hematol Educ Program -(-): 240-5 (2006)
2006  
13
Role of JAK-STAT signaling in the pathogenesis of myeloproliferative disorders.
[17124066] Hematology Am Soc Hematol Educ Program -(-): 233-9, 510 (2006)
2007  
14
Navigating the evolving paradigms in the diagnosis and treatment of myeloproliferative disorders.
[18024651] Hematology Am Soc Hematol Educ Program -(-): 355-62 (2007)
2008  
15
The JAK2V617F mutation in polycythemia vera and other myeloproliferative disorders: one mutation for three diseases?
[19074061] Hematology Am Soc Hematol Educ Program -(-): 69-75 (2008)
2010  
16
Thalidomide and lenalidomide in primary myelofibrosis.
[20739725] Neth J Med 68(1): 293-8 (2010)
2010  
17
Treatment considerations for primary myelofibrosis.
[20739724] Neth J Med 68(1): 291-2 (2010)
2008  
18
Myeloproliferative syndromes: diagnosis and therapeutic options.
[19202955] Pol Arch Med Wewn 118(12): 756-60 (2008)
2009  
19
Allogeneic hematopoietic cell transplantation for patients with myelofibrosis.
[19468277] Curr Opin Hematol 16(2): 140-6 (2009)
2007  
20
The chronic myeloproliferative disorders and mutation of JAK2: Dameshek's 54 year old speculation comes of age.
[17336249] Best Pract Res Clin Haematol 20(1): 5-12 (2007)

Downloaded from http://www.kidney.de - The Database of Free Medical Reviews - The Metatextbook of Medicine - Ossip Groth

All Medline data shown were primarily retrieved from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.


Fatal error: Uncaught Error: Call to undefined function mysql_connect() in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\Myelofibrosis.php:92 Stack trace: #0 {main} thrown in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\Myelofibrosis.php on line 92